TRANS GENIC GROUP INC. (2342) Cash flow
Market cap
¥3.6B
P/E ratio
23.8x
Transgenics Group supports drug development through specialized lab services like genetically modified mice production and pharmaceutical testing, while also providing business consulting and importing various products from electrical equipment to tableware.
| 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Depreciation & amortization | 57 | 66 | 75 | 93 | 124 | 149 | 170 | 152 | 124 | 106 | 140 | 108 |
| Cash from operations | 101 | 214 | 233 | 219 | 148 | -21 | 1,222 | 1,789 | -1,430 | -392 | 94 | 26 |
| Capital expenditures | -44 | -96 | -127 | -74 | -320 | -257 | -146 | -532 | -306 | -266 | -175 | -68 |
| Cash from investing | -47 | -665 | -200 | -552 | -835 | -319 | 48 | 982 | -216 | -281 | -288 | 51 |
| Payments for dividends | - | - | - | - | - | - | - | -52 | -101 | -84 | -50 | -0 |
| Repurchases of common stock | - | - | - | - | - | - | - | -299 | - | -79 | - | - |
| Proceeds from issuance of term debt, net | - | - | - | 300 | 125 | 315 | 765 | 220 | 1,240 | 210 | 600 | 340 |
| Repayments of term debt | - | - | - | -185 | -461 | -172 | -249 | -328 | -386 | -620 | -465 | -747 |
| Cash from financing | -93 | 158 | -27 | 1,045 | 194 | 667 | 10 | -1,183 | 485 | -343 | 265 | -518 |